US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TuHURA Biosciences, Inc.

2.22

-0.0700-3.06%

Post-market: 2.220.00000.00%19:34 EDT

Volume:2.95M

Turnover:6.54M

Market Cap:96.97M

PE:-2.40

High:2.36

Open:2.29

Low:2.10

Close:2.29

Loading ...

Overview Company News Filings

Tuhura Biosciences Increases Authorized Shares to 200 Million

BRIEF-Tuhura Biosciences Initiates Its Phase 3 Accelerated Approval Trial Of IFx-2.0

TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma

Tuhura Biosciences Inc: Primary Endpoint of Overall Response Rate (Orr) Qualifies for Accelerated Approval Process

THOMSON REUTERS

Tuhura Biosciences Inc -Key Secondary Endpoint of Progression Free Survival (Pfs) May Satisfy Requirement for a Post Confirmatory Trial

THOMSON REUTERS

Tuhura Biosciences Initiates Its Phase 3 Accelerated Approval Trial of Ifx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

THOMSON REUTERS

TuHURA Biosciences, Kineta stockholders approve merger and related proposals

Tuhura Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

THOMSON REUTERS

Press Release: TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Brookline Capital Initiates Coverage on TuHURA Biosciences With Buy Rating, $9 Price Target

MT Newswires Live

Tuhura Biosciences Inc. Increases CEO and CFO Salaries as Part of New Compensation Plan Effective June 2025

TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0

FDA Removes Partial Clinical Hold on Tuhura Biosciences' Phase 3 Accelerated Approval Trial for Ifx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

THOMSON REUTERS

TuHURA Biosciences Inc. Secures $12.5 Million for Phase 3 Trial of IFx-2.0 and Initiates Phase 2 Study on VISTA Inhibiting Antibody

BRIEF-Tuhura Biosciences Secures $12.5 Mln In Private Offering

Tuhura Biosciences-Plans to Use Net Proceeds From Offering to Fund Cash Requirements for Closing Proposed Merger With Kineta

THOMSON REUTERS

Tuhura Biosciences Inc -Secures $12.5 Mln of Commitments in a Private Offering

THOMSON REUTERS

Press Release: TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

TuHURA Biosciences Announces Phase 3 Trial for IFx-Hu2.0 as Adjunctive Therapy in Advanced Merkel Cell Carcinoma at ASCO 2025

Tuhura Biosciences Presents Ifx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HURA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":2.22,"timestamp":1751054400000,"preClose":2.29,"halted":0,"volume":2953412,"hourTrading":{"tag":"盘后","latestPrice":2.22,"preClose":2.22,"latestTime":"19:34 EDT","volume":798117,"amount":1771966.5757,"timestamp":1751067259253},"delay":0,"floatShares":21286907,"shares":43680397,"eps":-0.924572,"marketStatus":"Market Closed","change":-0.07,"latestTime":"06-27 16:00:00 EDT","open":2.29,"high":2.36,"low":2.1,"amount":6541610.8827608,"amplitude":0.113537,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.924572,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.29,"preHourTrading":{"tag":"盘前","latestPrice":2.28,"preClose":2.29,"latestTime":"09:25 EDT","volume":944,"amount":2219.5981248,"timestamp":1751030708686},"postHourTrading":{"tag":"盘后","latestPrice":2.22,"preClose":2.22,"latestTime":"19:34 EDT","volume":798117,"amount":1771966.5757,"timestamp":1751067259253},"volumeRatio":4.623038697161523},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":21286907,"roa":"-90.68%","roe":"-332.67%","lyrEps":-1.213628,"volumeRatio":4.623038697161523,"shares":43680397,"dividePrice":0,"high":2.36,"amplitude":0.113537,"preClose":2.29,"low":2.1,"week52Low":1.8,"pbRate":"10.12","week52High":11.8125,"institutionHeld":0,"latestPrice":2.22,"eps":-0.924572,"divideRate":0,"volume":2953412,"delay":0,"ttmEps":-0.924572,"open":2.29,"prevYearClose":4.09,"prevWeekClose":2.55,"prevMonthClose":3.06,"prevQuarterClose":3.23,"fiveDayClose":2.55,"twentyDayClose":3.18,"sixtyDayClose":2.91},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546149447","title":"Tuhura Biosciences Increases Authorized Shares to 200 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2546149447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546149447?lang=en_us&edition=fundamental","pubTime":"2025-06-27 18:01","pubTimestamp":1751018492,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has announced an amendment to its Articles of Incorporation, approved by stockholders at a recent special meeting. The amendment increases the number of authorized shares of common stock from 75 million to 200 million. The company has filed the necessary documentation with the Nevada Secretary of State to effectuate this change.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL55N8bm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2545328406","title":"BRIEF-Tuhura Biosciences Initiates Its Phase 3 Accelerated Approval Trial Of IFx-2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2545328406","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545328406?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:09","pubTimestamp":1750766988,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Initiates Its Phase 3 Accelerated Approval Trial Of IFx-2.0June 24 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES INITIATES ITS PHASE 3 ACCELERATED APPROVAL TRIA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nFWN3SR0HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2545284228","title":"TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284228","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284228?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:01","pubTimestamp":1750766504,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL2mzcpp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2545328412","title":"Tuhura Biosciences Inc: Primary Endpoint of Overall Response Rate (Orr) Qualifies for Accelerated Approval Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2545328412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545328412?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:00","pubTimestamp":1750766426,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nFWN3SR0HM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2545284493","title":"Tuhura Biosciences Inc -Key Secondary Endpoint of Progression Free Survival (Pfs) May Satisfy Requirement for a Post Confirmatory Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284493?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:00","pubTimestamp":1750766426,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nFWN3SR0HM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2545284120","title":"Tuhura Biosciences Initiates Its Phase 3 Accelerated Approval Trial of Ifx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284120?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:00","pubTimestamp":1750766426,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nFWN3SR0HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2545329428","title":"TuHURA Biosciences, Kineta stockholders approve merger and related proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2545329428","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545329428?lang=en_us&edition=fundamental","pubTime":"2025-06-24 05:05","pubTimestamp":1750712717,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (HURA) announced with Kineta (KANT) that TuHURA stockholders approved all of the proposals set forth at the company’s special me...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-kineta-stockholders-approve-merger-and-related-proposals-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-kineta-stockholders-approve-merger-and-related-proposals-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KANT","HURA","BK4139"],"gpt_icon":0},{"id":"2545264440","title":"Tuhura Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2545264440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545264440?lang=en_us&edition=fundamental","pubTime":"2025-06-24 05:00","pubTimestamp":1750712403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA60J264:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KANT","HURA"],"gpt_icon":0},{"id":"2545544046","title":"Press Release: TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2545544046","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545544046?lang=en_us&edition=fundamental","pubTime":"2025-06-24 05:00","pubTimestamp":1750712400,"startTime":"0","endTime":"0","summary":"TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc.  , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, that TuHURA stockholders approved all of the proposals set forth at the Company's Special Meeting of Stockholders held today, June 23, 2025 . The proposals included an increase of the Company's authorized shares to 200 million shares and a proposal to reincorporate the Company in Delaware.Additionally, Kineta stockholders approved the proposed merger  with TuHURA at Kineta's Special Meeting of Stockholders held today, June 23, 2025 . The parties anticipate that the Merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.The final voting results of the TuHURA Specia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4139","BK4232","HURA","BK4022","KANT"],"gpt_icon":0},{"id":"2545410443","title":"Brookline Capital Initiates Coverage on TuHURA Biosciences With Buy Rating, $9 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2545410443","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545410443?lang=en_us&edition=fundamental","pubTime":"2025-06-23 22:00","pubTimestamp":1750687259,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (HURA) has an average rating of Buy and mean price target of $12.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRKL","HURA"],"gpt_icon":0},{"id":"2542696515","title":"Tuhura Biosciences Inc. Increases CEO and CFO Salaries as Part of New Compensation Plan Effective June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542696515","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542696515?lang=en_us&edition=fundamental","pubTime":"2025-06-12 19:01","pubTimestamp":1749726073,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has announced updated compensation terms for its top executives. Effective June 6, 2025, the company's Compensation Committee approved an increase in the annual base salaries of James A. Bianco, M.D., Chief Executive Officer, to $577,101, and Dan Dearborn, Chief Financial Officer, to $384,453. Additionally, the Committee has finalized the fiscal year 2024 annual incentive bonuses for these executives, reflecting adjustments based on compensation practices and trends from a peer group analysis. The revised compensation aims to align the executives' salaries to approximately 90% of the 50th percentile of base salary levels within their peer group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL274YtD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2542810103","title":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2542810103","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542810103?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:00","pubTimestamp":1749470454,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Secures Additional $2.23 Million Funding Following FDA's Removal of Partial Clinical Hold on Phase 3 Trial for IFx-2.0. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL9Vnkv2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2542817643","title":"FDA Removes Partial Clinical Hold on Tuhura Biosciences' Phase 3 Accelerated Approval Trial for Ifx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2542817643","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542817643?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:00","pubTimestamp":1749470414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nFWN3SA07B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2541931838","title":"TuHURA Biosciences Inc. Secures $12.5 Million for Phase 3 Trial of IFx-2.0 and Initiates Phase 2 Study on VISTA Inhibiting Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2541931838","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541931838?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:43","pubTimestamp":1749242589,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc. Secures $12.5 Million for Phase 3 Trial of IFx-2.0 and Initiates Phase 2 Study on VISTA Inhibiting Antibody. TuHURA Biosciences, Inc. has announced plans to initiate a Phase 3 accelerated approval trial for its treatment IFx-2.0, targeting 40% enrollment by the end of 2025. The company has secured $12.5 million in commitments through a private offering and an additional $3.0 million from warrant exercises to support this initiative. The funding will also facilitate the acquisition and initiation of a Phase 2 trial in NPM1 mutated acute myeloid leukemia  through the closing of a merger with Kineta, Inc. Currently, there are no results available from these studies, as the trials and acquisitions are in the planning and initiation stages.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL95Y9sW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KANT","BK4139","HURA"],"gpt_icon":0},{"id":"2540777769","title":"BRIEF-Tuhura Biosciences Secures $12.5 Mln In Private Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2540777769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540777769?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:11","pubTimestamp":1748959888,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Secures $12.5 Mln In Private OfferingJune 3 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES INC -SECURES $12.5 MILLION OF COMMITMENTS IN A PRIVATE OFFERINGTUHURA ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2540777933","title":"Tuhura Biosciences-Plans to Use Net Proceeds From Offering to Fund Cash Requirements for Closing Proposed Merger With Kineta","url":"https://stock-news.laohu8.com/highlight/detail?id=2540777933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540777933?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:58","pubTimestamp":1748959100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60C4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2540677756","title":"Tuhura Biosciences Inc -Secures $12.5 Mln of Commitments in a Private Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2540677756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540677756?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:58","pubTimestamp":1748959100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2540977763","title":"Press Release: TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2540977763","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540977763?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:58","pubTimestamp":1748959080,"startTime":"0","endTime":"0","summary":"Secures $12.5 million of commitments in a private offering. Secures an additional $3.0 million through payment of cash exercise price of warrants. -- Acquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a. novel VISTA inhibiting antibody through closing of Kineta merger. Under the definitive agreement, approximately $9.0 million of the total offering amount will be purchased in four equal tranches based on the Company's achievement of certain milestones , and the remaining $3.5 million is required to be purchased and funded by December 31, 2025. One-fourth of the Initial Funding Amount will be purchased and funded at the initial closing of the offering, which is anticipated to be held on June 4, 2025 , with the remaining three tranches of the Initial Funding Amount to be purchased and funded based on the achievement of the following three milestones  if and when the applicable milestone is achieved:. -- One-fourth of the Initial Funding Amount will be purchased and funded","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","EQR","BK4232","BK4215","BK4588","HURA","BK4139","BK4231","BK4080","BK4022","BK4585","ADC"],"gpt_icon":0},{"id":"2540764760","title":"TuHURA Biosciences Announces Phase 3 Trial for IFx-Hu2.0 as Adjunctive Therapy in Advanced Merkel Cell Carcinoma at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540764760","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540764760?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:03","pubTimestamp":1748865800,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Announces Phase 3 Trial for IFx-Hu2.0 as Adjunctive Therapy in Advanced Merkel Cell Carcinoma at ASCO 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL9Bwhcw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2540602457","title":"Tuhura Biosciences Presents Ifx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540602457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540602457?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:03","pubTimestamp":1748865783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA9MSBXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"HURA","fiscalQuarterEnding":"2025/03","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37},{"market":"US","date":"2024-10-18","symbol":"HURA","defaultRemindTime":1729258200000,"type":"split","dateTimestamp":1729224000000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2024-10-07","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728273600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1747454400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2025-06-27","current":-4.255694,"percent":0.993902,"low":-15.284879,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"high":-4.144191,"avg":-8.119811,"sd":2.482296,"marketCap":100028109},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109}],"updateTime":1751167814004}}}